Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Diazyme Laboratories Inc Company Overview 5

Diazyme Laboratories Inc Company Snapshot 5

Diazyme Laboratories Inc Pipeline Products and Ongoing Clinical Trials Overview 5

Diazyme Laboratories Inc – Pipeline Analysis Overview 8

Diazyme Laboratories Inc - Key Facts 8

Diazyme Laboratories Inc - Major Products and Services 9

Diazyme Laboratories Inc Pipeline Products by Development Stage 10

Diazyme Laboratories Inc Pipeline Products Overview 12

B7-H4 Assay 12

B7-H4 Assay Product Overview 12

DcR3 (DD-C248) Assay 13

DcR3 (DD-C248) Assay Product Overview 13

MIC-1 (DD-X065) Assay 14

MIC-1 (DD-X065) Assay Product Overview 14

ProADM Point-of-Care 15

ProADM Point-of-Care Product Overview 15

ProADM Test 16

ProADM Test Product Overview 16

ProANP Test 17

ProANP Test Product Overview 17

ProET1 Test 18

ProET1 Test Product Overview 18

Spondin-2 (DD-P108) Assay 19

Spondin-2 (DD-P108) Assay Product Overview 19

TRAIL-R2 Assay 20

TRAIL-R2 Assay Product Overview 20

Diazyme Laboratories Inc - Key Competitors 21

Diazyme Laboratories Inc - Key Employees 22

Diazyme Laboratories Inc - Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Diazyme Laboratories Inc, Recent Developments 24

Jul 16, 2018: Ortho Clinical Diagnostics Launches New MicroTip Partnership Assays for Diabetes, Cardiac and Renal Testing, In Collaboration with Diazyme Laboratories 24

Jan 25, 2018: Stryker’s DAWN Trial results contribute to updated acute ischemic stroke guidelines from the American Heart Association and American Stroke Association 24

Jan 22, 2018: FDA Grants Diazyme 510(k) Clearance to Market Its New EZ Vitamin D Assay for Clinical Chemistry Analyzers 25

Jun 21, 2017: Beckman Coulter Diagnostics Expands Chemistry Menu to Include FDA-cleared Procalcitonin 25

Nov 28, 2016: FDA Grants Diazyme 510(k) Clearance to Market Its Direct HbA1c (Enzymatic, On-Board Lysis) Assay for Clinical Chemistry Analyzers 25

Nov 21, 2016: FDA Grants Diazyme 510(k) Clearance to Market Its Folate Assay for Clinical Chemistry Analyzers 26

Nov 21, 2016: FDA Grants Diazyme 510(k) Clearance to Market Its Vitamin B12 Assay for Clinical Chemistry Analyzers 26

Jul 22, 2016: Get Reliable Results with the Diazyme 25-OH Vitamin D Assay for Clinical Chemistry Analyzers 26

May 23, 2016: Diadexus and Sonic Healthcare USA Sign National Agreement for PLAC Activity Test 27

Nov 10, 2015: Diadexus Presents New PLAC Activity Data From the REGARDS Study at 2015 American Heart Association Scientific Sessions 27

Appendix 29

Methodology 29

About GlobalData 32

Contact Us 32

Disclaimer 32

Summary

Diazyme Laboratories Inc (Diazyme Laboratories) is a diagnostic reagents developer. The company offers test kits for diagnosis of cardiovascular disease, liver disease, cancer markers, renal disease, diabetes, and electrolytes. It offers products by markers, instrument specific packaging, point of care, DZ lite instrument, analyzer parameters, data sheets. Diazyme Laboratories offers anemia markers, cancer markers, cardiovascular markers, coagulation markers, diabetic markers, electrolyte markers, inflammatory markers, liver markers, renal and pancreatic marker, sepsis marker and vitamin marker. The company’s technology comprise enzyme cycling technology, latex enhanced immunoassay and enzyme-immunoassay. Diazyme Laboratories is headquartered in Poway, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Diazyme Laboratories Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company